ReviewInternational journal of nanomedicine2026
Source-Specific Extracellular Vesicle Functions and Engineering Strategies for Chronic Pain Management: A Comprehensive Review.
Review in International journal of nanomedicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Extracellular vesicles for next-gen therapeutics and drug delivery.Molecular biomedicine · 2026Review
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chronic pain management faces significant limitations due to adverse effects and insufficient long-term relief from existing therapies. Extracellular vesicles (EVs) are lipid bilayer-enclosed particles naturally carrying proteins, nucleic acids, and metabolites. Recently, EVs have emerged as a potential alternative approach. This review examines EVs from mesenchymal stem cells, neural cells, macrophages, and gut microbiota. EV activity is then assessed across the three major pain types defined by the ICD‑11: nociceptive pain, neuropathic pain, and nociplastic pain. We elucidate how source-specific EVs dynamically regulate different kinds of pain through multi-modal mechanisms, including neural signal transduction, neuroimmune axis coordination, structural neural repair, and metabolic network reprogramming. Furthermore, we discuss how these inherent therapeutic properties can be augmented through engineering approaches such as surface modification and cargo encapsulation, which enhance targeting and payload delivery. By integrating mechanistic insights into source‑specific EV functions with emerging engineering strategies, this review may provide a rational framework for developing next‑generation EV‑based analgesics. We conclude that harnessing the innate biological properties of EVs, complemented by strategic engineering, represents a potential non-opioid strategy for precise and effective management of chronic pain.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.